Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Chengdu Usano Biotechnology

Request full access

Allogeneic universal CAR-T cell therapeutic drug development

Chengdu, ChinaFounded 2020Biotech & Life Sciences

About Chengdu Usano Biotechnology

Chengdu Usano Biotechnology, also known as Ucello Therapeutics, is a biotechnology company established in 2020 with headquarters in Chengdu, Sichuan, China. The firm concentrates on the research and development of allogeneic universal CAR-T cell therapy drugs. Ucello's proprietary CBT-X20 technology platform utilizes lentiviral infection of T-cells, gene editing, in-vitro cultivation, expansion, and cryopreservation techniques. This platform aims to create "off-the-shelf" cell therapies for treating solid tumors and hematologic malignancies. A key product, UC101, is noted as the first FDA IND-approved allogeneic CAR-T therapy derived from umbilical cord blood.

The company's approach to manufacturing employs a stable producer cell line for the lentiviral vector, which avoids the need for plasmid DNA and is designed to lower production costs and improve consistency between batches. By using umbilical cord blood, a single batch can potentially be sufficient to treat over 100 patients, enhancing the accessibility of CAR-T therapy. Ucello operates on a B2B model within the biotech and pharmaceutical industry, developing therapies that target cancer cells at a molecular level. This allows treatment for patients who may have previously been ineligible for such therapies due to lymphocyte levels or transplant relapse history.

In February 2022, Ucello Therapeutics secured US$25 million in a Series A funding round. The round was led by Matrix Partners China and included participation from Co-Win Ventures, Northern Light Venture Capital, and Elikon Venture. The stated purpose of the funding was to advance the development of its universal CAR-T technology platform, progress its pipeline programs, and establish GMP-ready clinical manufacturing facilities. The company is led by CEO Dr. Qiang Zou.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jun 2023 $21M $125M Matrix Partners China · Cowin Venture · Shenzhen Guozhong Venture Capital Management · Juke Investment ↗
SERIES A✓Equity / VC Feb 2022 $25M $100M Elikon Venture · NLVC · Chengdu Bio-town Fund · Cowin Venture ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Chengdu Usano Biotechnology website traffic

Latest recorded traffic for Chengdu Usano Biotechnology is 120 monthly website visits, down 91.4% over the last three months.

Latest monthly visits120 3-month web change-91.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Chengdu Usano Biotechnology in the Chengdu ecosystem

Live from Dealroom

The Chengdu Usano Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Matrix Partners China
  • Elikon Venture
  • NLVC
  • Chengdu Bio-town Fund
  • Cowin Venture
  • Shenzhen Guozhong Venture Capital Management
  • Juke Investment
  • Guosheng Capital
  • Penglai Capital

Other known investors1 additional known investor

  • Chengdu Medical College
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Chengdu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Chengdu Usano Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Chengdu Usano Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.